Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.

Basit Öğe Kaydı
dc.authorwosidliu, xq/JDW-2596-2023
dc.authorwosidLiu, Yinuo/IZD-6086-2023
dc.contributor.authorSelvaggi, G.
dc.contributor.authorWu, Y.
dc.contributor.authorWang, Z.
dc.contributor.authorWu, G.
dc.contributor.authorPoddubskaya, E.
dc.contributor.authorReck, M.
dc.contributor.authorMok, T.
dc.date.accessioned2024-06-12T10:51:11Z
dc.date.available2024-06-12T10:51:11Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS233en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3en_US
dc.identifier.startpageS232en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18274
dc.identifier.volume16en_US
dc.identifier.wosWOS:000631349600306en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectALKen_US
dc.subjectNSCLCen_US
dc.subjectEnsartiniben_US
dc.titleQuality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu